[Hengrui Medicine: Subsidiary HRS-7535 Tablets Marketing Application Accepted] On September 2, Hengrui Medicine (600276.SH) announced that the company's subsidiary Shandong Shengdi Medicine received the "Notice of Acceptance" from the State Food and Drug Administration, and the drug marketing authorization application for HRS-7535 tablets was accepted. The proposed indication is blood sugar control in adults with type 2 diabetes. The drug is a new oral small molecule GLP-1R agonist. This application is based on two key phase III clinical studies. The results showed that the glycated hemoglobin decreased by 1.40%-1.68% in each dose group, while showing multi-dimensional benefits such as weight loss and urinary protein reduction.